Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Jun 01, 2017 12:27 pm UTC| Business
-- Clinical trial to evaluate orally-administered beta-lactam/beta-lactamase inhibitor combination being developed for infections due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae -- --...
Immunomedics to Present at Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 12:26 pm UTC| Business
MORRIS PLAINS, N.J., June 01, 2017 -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that Michael R. Garone, Vice President, Finance and Chief Financial Officer, will present at...
Immunomedics to Present at Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 12:26 pm UTC| Business
MORRIS PLAINS, N.J., June 01, 2017 -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today announced that Michael R. Garone, Vice President, Finance and Chief Financial Officer, will present at...